Broker Newswire
  • Home
  • Latest News
  • Investing
    • Acquisitions
    • Broker Related
    • Online Trading
    • Cryptocurrencies
    • Stocks
  • Markets
    • Earnings
    • OTC Markets
    • Penny Stocks
  • Personal Finance
    • Saving money
    • Retirement
  • Economy
  • Tech
    • Enterprise
    • Internet
SUBSCRIBE
No Result
View All Result
  • Home
  • Latest News
  • Investing
    • Acquisitions
    • Broker Related
    • Online Trading
    • Cryptocurrencies
    • Stocks
  • Markets
    • Earnings
    • OTC Markets
    • Penny Stocks
  • Personal Finance
    • Saving money
    • Retirement
  • Economy
  • Tech
    • Enterprise
    • Internet
No Result
View All Result
Broker Newswire
No Result
View All Result
Home Latest News General

Aegerion Pharmaceuticals Agrees To Pay $4.1 Million To Settle Claims It Misled Investors

by Jay Helton
September 22, 2017
1 min read
0
sec logo
Share on FacebookShare on Twitter

On September 22, 2017, the Securities and Exchange Commission filed fraud charges against a Massachusetts biopharmaceutical company. The company was accused of exaggerating the number of new patients that had filled prescriptions for the company’s expensive drug, which just happened to be its only source of revenue. Aegerion Pharmaceuticals has agreed to pay $4.1 million to settle claims that is misled investors numerous times in 2013.

The company is now a subsidiary of Novelion Therapeutics. The SEC’s complaint suggests that Aegerion told investors that most prescriptions for Juxtapid were filled by consumers. In reality, the SEC claims that company records indicate that roughly half of the prescriptions resulted in drug purchases.

The complaint explains that Juxtapid is designed to combat a rare genetic condition, which causes excessively high cholesterol. In 2013 and 2014, the drug was priced at roughly $250,000 to $300,000 each year per patient. When Juxtapid was introduced in 2013, investors and analysts had very little data to estimate the drug’s future revenues.

RELATED STORIES

Volkswagen must pay damages

Volkswagen must pay damages to buyers of manipulated diesel cars

May 25, 2020
Future Cloud Banking and Fintech

Future Cloud Predictions for Banking and Fintech Sector

April 23, 2020

During several earnings calls, Aegerion supposedly provided details about prescriptions related to the drug. This information was deemed insufficient, since not all prescriptions ultimately converted into sales. The SEC complaint claims that the real conversion rate within the range of 50 to 60 percent wasn’t actually disclosed until October of 2014.

The complaint also suggests that Aegerion never notified investors that the conversion rate was around 50 percent in 2013. The company has agreed to settle the allegations without admitting or denying guilt. Again, Aegerion Pharmaceuticals will pay $4.1 million to settle the charges.

Tags: aegerionnovelionnovelion therapeuticspharmaceuticals
Create your Web Presence with Namecheap

Recent Posts

  • Bitcoin and crypto spending is allowed by PayPal Now
  • The event in the live stream: Apple releases 5G-capable iPhone – Business
  • Volkswagen thriller: An unpopular supplier, audio recordings and a dead man
  • Tencent and WeChat also affected: Why Trump’s TikTok ban could harm Silicon Valley
  • Hacker attack on Twitter: “Group of young people” is supposed to be behind the attack on the social media platform

Category

  • Acquisitions
  • Broker Related
  • Earnings Reports
  • Economy
  • Enterprise
  • General
  • Internet
  • Investing
  • IPO News
  • Latest News
  • Layoffs
  • Markets
  • Online Trading
  • Opinion
  • OTC Markets
  • Penny Stocks
  • Personal Finance
  • Retirement
  • Saving money
  • Stocks
  • Technology

About Us

Broker Newswire (BN) is an exciting new online publication, which targets finances, brokers, mortgage and markets. BN, which is the nation’s leading provider of real estate, finance and market news and analysis.

  • About
  • Advertise
  • Privacy & Policy
  • Feedback

© 2021 JNews - Premium WordPress news & magazine theme by Jegtheme.

No Result
View All Result
  • Home
  • Latest News
  • Investing
    • Acquisitions
    • Broker Related
    • Cryptocurrencies
    • Online Trading
    • Stocks
  • Markets
    • Earnings Reports
    • OTC Markets
    • Penny Stocks
  • Personal Finance
    • Retirement
    • Saving money
  • Economy
  • Tech
    • Enterprise
    • Internet
This website uses cookies. By continuing to use this website you are giving consent to cookies being used. Visit our Privacy and Cookie Policy.